BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sakurai T, Mieda M, Tsujino N. The orexin system: roles in sleep/wake regulation: Orexin and sleep/wake state. Annals of the New York Academy of Sciences 2010;1200:149-61. [DOI: 10.1111/j.1749-6632.2010.05513.x] [Cited by in Crossref: 125] [Cited by in F6Publishing: 111] [Article Influence: 10.4] [Reference Citation Analysis]
Number Citing Articles
1 Abbott M, Volkoff H. Thyrotropin Releasing Hormone (TRH) in goldfish (Carassius auratus): Role in the regulation of feeding and locomotor behaviors and interactions with the orexin system and cocaine- and amphetamine regulated transcript (CART). Hormones and Behavior 2011;59:236-45. [DOI: 10.1016/j.yhbeh.2010.12.008] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 3.9] [Reference Citation Analysis]
2 Cun Y, Tang L, Yan J, He C, Li Y, Hu Z, Xia J. Orexin A attenuates the sleep-promoting effect of adenosine in the lateral hypothalamus of rats. Neurosci Bull 2014;30:877-86. [PMID: 24898402 DOI: 10.1007/s12264-013-1442-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
3 Roundtree HM, Simeone TA, Johnson C, Matthews SA, Samson KK, Simeone KA. Orexin Receptor Antagonism Improves Sleep and Reduces Seizures in Kcna1-null Mice. Sleep 2016;39:357-68. [PMID: 26446112 DOI: 10.5665/sleep.5444] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Matzeu A, Kallupi M, George O, Schweitzer P, Martin-Fardon R. Dynorphin Counteracts Orexin in the Paraventricular Nucleus of the Thalamus: Cellular and Behavioral Evidence. Neuropsychopharmacology 2018;43:1010-20. [PMID: 29052613 DOI: 10.1038/npp.2017.250] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 4.6] [Reference Citation Analysis]
5 Schneider NY, Chaudy S, Epstein AL, Viollet C, Benani A, Pénicaud L, Grosmaître X, Datiche F, Gascuel J. Centrifugal projections to the main olfactory bulb revealed by transsynaptic retrograde tracing in mice. J Comp Neurol 2020;528:1805-19. [PMID: 31872441 DOI: 10.1002/cne.24846] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
6 Kumar A, Chanana P, Choudhary S. Emerging role of orexin antagonists in insomnia therapeutics: An update on SORAs and DORAs. Pharmacological Reports 2016;68:231-42. [DOI: 10.1016/j.pharep.2015.09.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
7 Adhikari P, Pradhan A, Zele AJ, Feigl B. Supplemental light exposure improves sleep architecture in people with type 2 diabetes. Acta Diabetol 2021;58:1201-8. [PMID: 33851274 DOI: 10.1007/s00592-021-01712-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Shi L, Ko ML, Abbott LC, Ko GY. Identification of Peptide lv, a novel putative neuropeptide that regulates the expression of L-type voltage-gated calcium channels in photoreceptors. PLoS One 2012;7:e43091. [PMID: 22912796 DOI: 10.1371/journal.pone.0043091] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
9 Christensen J, Yamakawa GR, Shultz SR, Mychasiuk R. Is the glymphatic system the missing link between sleep impairments and neurological disorders? Examining the implications and uncertainties. Prog Neurobiol 2021;198:101917. [PMID: 32991958 DOI: 10.1016/j.pneurobio.2020.101917] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
10 Wang C, Han X, Guo F, Sun X, Luan X, Xu L. Orexin-A signaling in the paraventricular nucleus modulates spontaneous firing of glucose-sensitive neurons and promotes food intake via the NPY pathway in rats. Biochem Biophys Res Commun 2018;505:162-7. [PMID: 30243725 DOI: 10.1016/j.bbrc.2018.09.091] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
11 Saitoh T, Seki K, Nakajima R, Yamamoto N, Kutsumura N, Nagumo Y, Irukayama-Tomobe Y, Ogawa Y, Ishikawa Y, Yanagisawa M, Nagase H. Essential structure of orexin 1 receptor antagonist YNT-707, part V: Structure-activity relationship study of the substituents on the 17-amino group. Bioorg Med Chem Lett 2020;30:126893. [PMID: 31879208 DOI: 10.1016/j.bmcl.2019.126893] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Torterolo P, Ramos OV, Sampogna S, Chase MH. Hypocretinergic neurons are activated in conjunction with goal-oriented survival-related motor behaviors. Physiol Behav 2011;104:823-30. [PMID: 21839102 DOI: 10.1016/j.physbeh.2011.07.032] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
13 Gibbs RB, Chipman AM, Hammond R, Nelson D. Galanthamine plus estradiol treatment enhances cognitive performance in aged ovariectomized rats. Horm Behav 2011;60:607-16. [PMID: 21889940 DOI: 10.1016/j.yhbeh.2011.08.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
14 Dingemanse J, Cruz HG, Gehin M, Hoever P. Pharmacokinetic interactions between the orexin receptor antagonist almorexant and the CYP3A4 inhibitors ketoconazole and diltiazem. J Pharm Sci 2014;103:1548-56. [PMID: 24604243 DOI: 10.1002/jps.23916] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
15 Jalewa J, Wong-lin K, Mcginnity TM, Prasad G, Hölscher C. Increased number of orexin/hypocretin neurons with high and prolonged external stress-induced depression. Behavioural Brain Research 2014;272:196-204. [DOI: 10.1016/j.bbr.2014.05.030] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 5.1] [Reference Citation Analysis]
16 Kotan D, Deniz O, Aygul R, Yildirim A. Acute cerebral ischaemia: relationship between serum and cerebrospinal fluid orexin-A concentration and infarct volume. J Int Med Res 2013;41:404-9. [PMID: 23569032 DOI: 10.1177/0300060513477002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
17 Li A, Nattie E. Orexin, cardio-respiratory function, and hypertension. Front Neurosci 2014;8:22. [PMID: 24574958 DOI: 10.3389/fnins.2014.00022] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Dingemanse J, Gehin M, Cruz HG, Hoever P. Formulation development for the orexin receptor antagonist almorexant: assessment in two clinical studies. Drug Des Devel Ther 2014;8:397-403. [PMID: 24812492 DOI: 10.2147/DDDT.S62118] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
19 Hoyer D, Jacobson LH. Orexin Receptor Antagonists. Curr Sleep Medicine Rep 2017;3:342-53. [DOI: 10.1007/s40675-017-0099-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
20 Heese K. G proteins, p60TRP, and neurodegenerative diseases. Mol Neurobiol 2013;47:1103-11. [PMID: 23345134 DOI: 10.1007/s12035-013-8410-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
21 Pinheiro da Silva F, Machado MC, Velasco IT. Neuropeptides in sepsis: from brain pathology to systemic inflammation. Peptides 2013;44:135-8. [PMID: 23583479 DOI: 10.1016/j.peptides.2013.03.029] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
22 Laburthe M, Voisin T. The orexin receptor OX(1)R in colon cancer: a promising therapeutic target and a new paradigm in G protein-coupled receptor signalling through ITIMs. Br J Pharmacol 2012;165:1678-87. [PMID: 21627633 DOI: 10.1111/j.1476-5381.2011.01510.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
23 Pintwala S, Peever J. Circuit mechanisms of sleepiness and cataplexy in narcolepsy. Current Opinion in Neurobiology 2017;44:50-8. [DOI: 10.1016/j.conb.2017.02.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
24 Burt J, Alberto CO, Parsons MP, Hirasawa M. Local network regulation of orexin neurons in the lateral hypothalamus. Am J Physiol Regul Integr Comp Physiol 2011;301:R572-80. [PMID: 21697524 DOI: 10.1152/ajpregu.00674.2010] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 4.5] [Reference Citation Analysis]
25 Katoh K, Kutsumura N, Yamamoto N, Nagumo Y, Saitoh T, Ishikawa Y, Irukayama-Tomobe Y, Tanimura R, Yanagisawa M, Nagase H. Essential structure of orexin 1 receptor antagonist YNT-707: Conversion of the 16-cyclopropylmethyl group to the 16-sulfonamide group in D-nor-nalfurafine derivatives. Bioorg Med Chem Lett 2022;:128550. [PMID: 35041942 DOI: 10.1016/j.bmcl.2022.128550] [Reference Citation Analysis]
26 Vécsei L, Lukács M, Tajti J, Fülöp F, Toldi J, Edvinsson L. The Therapeutic Impact of New Migraine Discoveries. Curr Med Chem 2019;26:6261-81. [PMID: 29848264 DOI: 10.2174/0929867325666180530114534] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
27 Lavezzi AM, Ferrero S, Roncati L, Matturri L, Pusiol T. Impaired orexin receptor expression in the Kölliker-Fuse nucleus in sudden infant death syndrome: possible involvement of this nucleus in arousal pathophysiology. Neurol Res 2016;38:706-16. [PMID: 27353953 DOI: 10.1080/01616412.2016.1201632] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
28 Chabi A, Zhang Y, Jackson S, Cady R, Lines C, Herring WJ, Connor KM, Michelson D. Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis. Cephalalgia 2015;35:379-88. [PMID: 25106663 DOI: 10.1177/0333102414544979] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 6.8] [Reference Citation Analysis]
29 Lavezzi AM, Piscioli F, Pusiol T, Jorizzo G, Ferrero S. Sudden intrauterine unexplained death: time to adopt uniform postmortem investigative guidelines? BMC Pregnancy Childbirth 2019;19:526. [PMID: 31888538 DOI: 10.1186/s12884-019-2603-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
30 Struyk A, Gargano C, Drexel M, Stoch SA, Svetnik V, Ma J, Mayleben D. Pharmacodynamic effects of suvorexant and zolpidem on EEG during sleep in healthy subjects. Eur Neuropsychopharmacol 2016;26:1649-56. [PMID: 27554636 DOI: 10.1016/j.euroneuro.2016.07.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
31 Steiner MA, Lecourt H, Jenck F. The dual orexin receptor antagonist almorexant, alone and in combination with morphine, cocaine and amphetamine, on conditioned place preference and locomotor sensitization in the rat. Int J Neuropsychopharmacol 2013;16:417-32. [PMID: 22436395 DOI: 10.1017/S1461145712000193] [Cited by in Crossref: 32] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
32 Lonstein JS, Linning‐duffy K, Tang Y, Moody A, Yan L. Impact of daytime light intensity on the central orexin (hypocretin) system of a diurnal rodent ( Arvicanthis niloticus ). Eur J Neurosci 2021;54:4167-81. [DOI: 10.1111/ejn.15248] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Connor KM, Mahoney E, Jackson S, Hutzelmann J, Zhao X, Jia N, Snyder E, Snavely D, Michelson D, Roth T, Herring WJ. A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary Insomnia. Int J Neuropsychopharmacol 2016;19:pyw022. [PMID: 26979830 DOI: 10.1093/ijnp/pyw022] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
34 Bjorness TE, Greene RW. Sleep Deprivation Enhances Cocaine Conditioned Place Preference in an Orexin Receptor-Modulated Manner. eNeuro 2020;7:ENEURO. [PMID: 33139319 DOI: 10.1523/ENEURO.0283-20.2020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Cengiz M, Karaj V, Kocabasoğlu N, Gozubatik-celik G, Dirican A, Bayoglu B. Orexin/hypocretin receptor, Orx 1 , gene variants are associated with major depressive disorder. International Journal of Psychiatry in Clinical Practice 2019;23:114-21. [DOI: 10.1080/13651501.2018.1551549] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
36 Donga E, Romijn JA. Sleep characteristics and insulin sensitivity in humans. Handb Clin Neurol 2014;124:107-14. [PMID: 25248582 DOI: 10.1016/B978-0-444-59602-4.00007-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
37 Gao XB. Plasticity in neurons synthesizing wake/arousal promoting hormone hypocretin/orexin. Vitam Horm 2012;89:35-59. [PMID: 22640607 DOI: 10.1016/B978-0-12-394623-2.00003-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
38 Svetnik V, Snyder ES, Tao P, Scammell TE, Roth T, Lines C, Herring WJ. Insight Into Reduction of Wakefulness by Suvorexant in Patients With Insomnia: Analysis of Wake Bouts. Sleep 2018;41. [DOI: 10.1093/sleep/zsx178] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
39 Arango M, Kivity S, Shoenfeld Y. Is narcolepsy a classical autoimmune disease? Pharmacological Research 2015;92:6-12. [DOI: 10.1016/j.phrs.2014.10.005] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
40 Matzeu A, Kerr TM, Weiss F, Martin-Fardon R. Orexin-A/Hypocretin-1 Mediates Cocaine-Seeking Behavior in the Posterior Paraventricular Nucleus of the Thalamus via Orexin/Hypocretin Receptor-2. J Pharmacol Exp Ther 2016;359:273-9. [PMID: 27540003 DOI: 10.1124/jpet.116.235945] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 7.0] [Reference Citation Analysis]
41 Viviani D, Haegler P, Jenck F, Steiner MA. Orexin neuropeptides contribute to the development and persistence of generalized avoidance behavior in the rat. Psychopharmacology (Berl) 2015;232:1383-93. [PMID: 25319964 DOI: 10.1007/s00213-014-3769-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
42 Denney WS, Sonnenberg GE, Carvajal-Gonzalez S, Tuthill T, Jackson VM. Pharmacokinetics and pharmacodynamics of PF-05190457: The first oral ghrelin receptor inverse agonist to be profiled in healthy subjects. Br J Clin Pharmacol 2017;83:326-38. [PMID: 27621150 DOI: 10.1111/bcp.13127] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
43 Matzeu A, Martin-Fardon R. Cocaine-Seeking Behavior Induced by Orexin A Administration in the Posterior Paraventricular Nucleus of the Thalamus Is Not Long-Lasting: Neuroadaptation of the Orexin System During Cocaine Abstinence. Front Behav Neurosci 2021;15:620868. [PMID: 33708078 DOI: 10.3389/fnbeh.2021.620868] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Cintron D, Beckman JP, Bailey KR, Lahr BD, Jayachandran M, Miller VM. Plasma orexin A levels in recently menopausal women during and 3 years following use of hormone therapy. Maturitas 2017;99:59-65. [PMID: 28364870 DOI: 10.1016/j.maturitas.2017.01.016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
45 Mavanji V, Perez-Leighton CE, Kotz CM, Billington CJ, Parthasarathy S, Sinton CM, Teske JA. Promotion of Wakefulness and Energy Expenditure by Orexin-A in the Ventrolateral Preoptic Area. Sleep 2015;38:1361-70. [PMID: 25845696 DOI: 10.5665/sleep.4970] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
46 Palouzier-Paulignan B, Lacroix MC, Aimé P, Baly C, Caillol M, Congar P, Julliard AK, Tucker K, Fadool DA. Olfaction under metabolic influences. Chem Senses 2012;37:769-97. [PMID: 22832483 DOI: 10.1093/chemse/bjs059] [Cited by in Crossref: 183] [Cited by in F6Publishing: 170] [Article Influence: 18.3] [Reference Citation Analysis]
47 Michelson D, Snyder E, Paradis E, Chengan-Liu M, Snavely DB, Hutzelmann J, Walsh JK, Krystal AD, Benca RM, Cohn M, Lines C, Roth T, Herring WJ. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol 2014;13:461-71. [PMID: 24680372 DOI: 10.1016/S1474-4422(14)70053-5] [Cited by in Crossref: 183] [Cited by in F6Publishing: 60] [Article Influence: 22.9] [Reference Citation Analysis]
48 Ma J, Svetnik V, Snyder E, Lines C, Roth T, Herring WJ. Electroencephalographic power spectral density profile of the orexin receptor antagonist suvorexant in patients with primary insomnia and healthy subjects. Sleep 2014;37:1609-19. [PMID: 25197807 DOI: 10.5665/sleep.4068] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
49 Yang C, Zhang L, Hao H, Ran M, Li J, Dong H. Serotonergic neurons in the dorsal raphe nucleus mediate the arousal-promoting effect of orexin during isoflurane anesthesia in male rats. Neuropeptides 2019;75:25-33. [DOI: 10.1016/j.npep.2019.03.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
50 Boof M, Alatrach A, Ufer M, Dingemanse J. Interaction potential of the dual orexin receptor antagonist ACT-541468 with CYP3A4 and food: results from two interaction studies. Eur J Clin Pharmacol 2019;75:195-205. [DOI: 10.1007/s00228-018-2559-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
51 Esposito M, Pellinen J, Kapás L, Szentirmai É. Impaired wake-promoting mechanisms in ghrelin receptor-deficient mice. Eur J Neurosci 2012;35:233-43. [PMID: 22211783 DOI: 10.1111/j.1460-9568.2011.07946.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
52 Jalewa J, Joshi A, McGinnity TM, Prasad G, Wong-Lin K, Hölscher C. Neural circuit interactions between the dorsal raphe nucleus and the lateral hypothalamus: an experimental and computational study. PLoS One 2014;9:e88003. [PMID: 24516577 DOI: 10.1371/journal.pone.0088003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
53 Kawabe K, Horiuchi F, Ochi M, Nishimoto K, Ueno SI, Oka Y. Suvorexant for the Treatment of Insomnia in Adolescents. J Child Adolesc Psychopharmacol 2017;27:792-5. [PMID: 28520464 DOI: 10.1089/cap.2016.0206] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 3.2] [Reference Citation Analysis]
54 Kawai N, Sakai N, Okuro M, Karakawa S, Tsuneyoshi Y, Kawasaki N, Takeda T, Bannai M, Nishino S. The sleep-promoting and hypothermic effects of glycine are mediated by NMDA receptors in the suprachiasmatic nucleus. Neuropsychopharmacology 2015;40:1405-16. [PMID: 25533534 DOI: 10.1038/npp.2014.326] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
55 Sakai N, Matsumura M, Lin L, Mignot E, Nishino S. HPLC analysis of CSF hypocretin-1 in type 1 and 2 narcolepsy. Sci Rep 2019;9:477. [PMID: 30679597 DOI: 10.1038/s41598-018-36942-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
56 Imperatore R, Palomba L, Cristino L. Role of Orexin-A in Hypertension and Obesity. Curr Hypertens Rep 2017;19. [DOI: 10.1007/s11906-017-0729-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
57 Zhou W, Wang LQ, Shao YQ, Han X, Yu CX, Yuan F, Wang X, Weng SJ, Zhong YM, Yang XL. Orexin-A Intensifies Mouse Pupillary Light Response by Modulating Intrinsically Photosensitive Retinal Ganglion Cells. J Neurosci 2021;41:2566-80. [PMID: 33536197 DOI: 10.1523/JNEUROSCI.0217-20.2021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
58 Brunert D, Rothermel M. Extrinsic neuromodulation in the rodent olfactory bulb. Cell Tissue Res 2021;383:507-24. [PMID: 33355709 DOI: 10.1007/s00441-020-03365-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
59 Pang TY, Yaeger JDW, Summers CH, Mitra R. Cardinal role of the environment in stress induced changes across life stages and generations. Neurosci Biobehav Rev 2021;124:137-50. [PMID: 33549740 DOI: 10.1016/j.neubiorev.2021.01.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 He D, Jiang B, Guo Z, Mu Q, Mcclure MA. Biphasic feature of placebo response in primary insomnia: pooled analysis of data from randomized controlled clinical trials of orexin receptor antagonists. Sleep 2020;43:zsz238. [PMID: 31593985 DOI: 10.1093/sleep/zsz238] [Reference Citation Analysis]
61 Stanley EM, Fadel JR. Aging-related alterations in orexin/hypocretin modulation of septo-hippocampal amino acid neurotransmission. Neuroscience 2011;195:70-9. [PMID: 21884758 DOI: 10.1016/j.neuroscience.2011.08.033] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
62 Nollet M, Gaillard P, Tanti A, Girault V, Belzung C, Leman S. Neurogenesis-independent antidepressant-like effects on behavior and stress axis response of a dual orexin receptor antagonist in a rodent model of depression. Neuropsychopharmacology 2012;37:2210-21. [PMID: 22713907 DOI: 10.1038/npp.2012.70] [Cited by in Crossref: 91] [Cited by in F6Publishing: 89] [Article Influence: 9.1] [Reference Citation Analysis]
63 Tang H, Zhu Q, Li W, Qin S, Gong Y, Wang H, Shioda S, Li S, Huang J, Liu B, Fang Y, Liu Y, Wang S, Guo Y, Xia Q, Guo Y, Xu Z. Neurophysiology and Treatment of Disorders of Consciousness Induced by Traumatic Brain Injury: Orexin Signaling as a Potential Therapeutic Target. Curr Pharm Des 2019;25:4208-20. [PMID: 31663471 DOI: 10.2174/1381612825666191029101830] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
64 Choi DL, Davis JF, Magrisso IJ, Fitzgerald ME, Lipton JW, Benoit SC. Orexin signaling in the paraventricular thalamic nucleus modulates mesolimbic dopamine and hedonic feeding in the rat. Neuroscience 2012;210:243-8. [PMID: 22433299 DOI: 10.1016/j.neuroscience.2012.02.036] [Cited by in Crossref: 87] [Cited by in F6Publishing: 76] [Article Influence: 8.7] [Reference Citation Analysis]
65 Plaza-Zabala A, Flores Á, Maldonado R, Berrendero F. Hypocretin/orexin signaling in the hypothalamic paraventricular nucleus is essential for the expression of nicotine withdrawal. Biol Psychiatry 2012;71:214-23. [PMID: 21831361 DOI: 10.1016/j.biopsych.2011.06.025] [Cited by in Crossref: 60] [Cited by in F6Publishing: 59] [Article Influence: 5.5] [Reference Citation Analysis]
66 Chase MH. A unified survival theory of the functioning of the hypocretinergic system. J Appl Physiol (1985) 2013;115:954-71. [PMID: 23640599 DOI: 10.1152/japplphysiol.00700.2012] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
67 Buguet A, Mpanzou G, Bentivoglio M. Human African Trypanosomiasis: A Highly Neglected Neurological Disease. In: Bentivoglio M, Cavalheiro EA, Kristensson K, Patel NB, editors. Neglected Tropical Diseases and Conditions of the Nervous System. New York: Springer; 2014. pp. 165-81. [DOI: 10.1007/978-1-4614-8100-3_9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
68 Saitoh T, Seki K, Nakajima R, Yamamoto N, Kutsumura N, Nagumo Y, Irukayama-Tomobe Y, Ogawa Y, Ishikawa Y, Tanimura R, Yanagisawa M, Nagase H. Essential structure of orexin 1 receptor antagonist YNT-707, Part IV: The role of D-ring in 4,5-epoxymorphinan on the orexin 1 receptor antagonistic activity. Bioorg Med Chem Lett 2019;29:2655-8. [PMID: 31375290 DOI: 10.1016/j.bmcl.2019.07.039] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
69 Alié A, Devos L, Torres-Paz J, Prunier L, Boulet F, Blin M, Elipot Y, Retaux S. Developmental evolution of the forebrain in cavefish, from natural variations in neuropeptides to behavior. Elife 2018;7:e32808. [PMID: 29405116 DOI: 10.7554/eLife.32808] [Cited by in Crossref: 34] [Cited by in F6Publishing: 12] [Article Influence: 8.5] [Reference Citation Analysis]
70 Matzeu A, Martin-Fardon R. Drug Seeking and Relapse: New Evidence of a Role for Orexin and Dynorphin Co-transmission in the Paraventricular Nucleus of the Thalamus. Front Neurol 2018;9:720. [PMID: 30210441 DOI: 10.3389/fneur.2018.00720] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
71 Schmidt FM, Arendt E, Steinmetzer A, Bruegel M, Kratzsch J, Strauß M, Baum P, Hegerl U, Schönknecht P. CSF-hypocretin-1 levels in patients with major depressive disorder compared to healthy controls. Psychiatry Research 2011;190:240-3. [DOI: 10.1016/j.psychres.2011.06.004] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
72 Ahmadi-soleimani SM, Mianbandi V, Azizi H, Azhdari-zarmehri H, Ghaemi-jandabi M, Abbasi-mazar A, Mohajer Y, Darana SP. Coregulation of sleep-pain physiological interplay by orexin system: An unprecedented review. Behavioural Brain Research 2020;391:112650. [DOI: 10.1016/j.bbr.2020.112650] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
73 Barson JR, Morganstern I, Leibowitz SF. Neurobiology of consummatory behavior: mechanisms underlying overeating and drug use. ILAR J 2012;53:35-58. [PMID: 23520598 DOI: 10.1093/ilar.53.1.35] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
74 Herring WJ, Connor KM, Ivgy-May N, Snyder E, Liu K, Snavely DB, Krystal AD, Walsh JK, Benca RM, Rosenberg R, Sangal RB, Budd K, Hutzelmann J, Leibensperger H, Froman S, Lines C, Roth T, Michelson D. Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials. Biol Psychiatry 2016;79:136-48. [PMID: 25526970 DOI: 10.1016/j.biopsych.2014.10.003] [Cited by in Crossref: 108] [Cited by in F6Publishing: 101] [Article Influence: 13.5] [Reference Citation Analysis]
75 Shankar A, Williams CT. The darkness and the light: diurnal rodent models for seasonal affective disorder. Dis Model Mech 2021;14:dmm047217. [PMID: 33735098 DOI: 10.1242/dmm.047217] [Reference Citation Analysis]
76 Tupone D, Madden CJ, Cano G, Morrison SF. An orexinergic projection from perifornical hypothalamus to raphe pallidus increases rat brown adipose tissue thermogenesis. J Neurosci 2011;31:15944-55. [PMID: 22049437 DOI: 10.1523/JNEUROSCI.3909-11.2011] [Cited by in Crossref: 147] [Cited by in F6Publishing: 94] [Article Influence: 13.4] [Reference Citation Analysis]
77 Katzav A, Arango MT, Kivity S, Tanaka S, Givaty G, Agmon-levin N, Honda M, Anaya J, Chapman J, Shoenfeld Y. Passive transfer of narcolepsy: Anti-TRIB2 autoantibody positive patient IgG causes hypothalamic orexin neuron loss and sleep attacks in mice. Journal of Autoimmunity 2013;45:24-30. [DOI: 10.1016/j.jaut.2013.06.010] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 4.7] [Reference Citation Analysis]
78 Hino T, Saitoh T, Nagumo Y, Yamamoto N, Kutsumura N, Irukayama-Tomobe Y, Ishikawa Y, Tanimura R, Yanagisawa M, Nagase H. Design and synthesis of novel orexin 2 receptor agonists based on naphthalene skeleton. Bioorg Med Chem Lett 2022;:128530. [PMID: 35007725 DOI: 10.1016/j.bmcl.2022.128530] [Reference Citation Analysis]
79 Karhu L, Weisell J, Turunen PM, Leino TO, Pätsi H, Xhaard H, Kukkonen JP, Wallén EAA. Stapled truncated orexin peptides as orexin receptor agonists. Peptides 2018;102:54-60. [PMID: 29475074 DOI: 10.1016/j.peptides.2018.02.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
80 Xiao F, Jiang M, Du D, Xia C, Wang J, Cao Y, Shen L, Zhu D. Orexin A regulates cardiovascular responses in stress-induced hypertensive rats. Neuropharmacology 2013;67:16-24. [PMID: 23147417 DOI: 10.1016/j.neuropharm.2012.10.021] [Cited by in Crossref: 55] [Cited by in F6Publishing: 59] [Article Influence: 5.5] [Reference Citation Analysis]
81 Pałasz A, Lapray D, Peyron C, Rojczyk-Gołębiewska E, Skowronek R, Markowski G, Czajkowska B, Krzystanek M, Wiaderkiewicz R. Dual orexin receptor antagonists - promising agents in the treatment of sleep disorders. Int J Neuropsychopharmacol 2014;17:157-68. [PMID: 23702225 DOI: 10.1017/S1461145713000552] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
82 Feng P, Akladious AA, Hu Y, Raslan Y, Feng J, Smith PJ. 7,8-Dihydroxyflavone reduces sleep during dark phase and suppresses orexin A but not orexin B in mice. J Psychiatr Res 2015;69:110-9. [PMID: 26343602 DOI: 10.1016/j.jpsychires.2015.08.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
83 Segal Y, Shoenfeld Y. Vaccine-induced autoimmunity: the role of molecular mimicry and immune crossreaction. Cell Mol Immunol 2018;15:586-94. [PMID: 29503439 DOI: 10.1038/cmi.2017.151] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 11.5] [Reference Citation Analysis]
84 Szentirmai É. Central but not systemic administration of ghrelin induces wakefulness in mice. PLoS One 2012;7:e41172. [PMID: 22815958 DOI: 10.1371/journal.pone.0041172] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
85 Gotter AL, Webber AL, Coleman PJ, Renger JJ, Winrow CJ. International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin Receptor Function, Nomenclature and Pharmacology. Pharmacol Rev 2012;64:389-420. [DOI: 10.1124/pr.111.005546] [Cited by in Crossref: 114] [Cited by in F6Publishing: 107] [Article Influence: 11.4] [Reference Citation Analysis]
86 Karhu L, Turku A, Xhaard H. Modeling of the OX1R-orexin-A complex suggests two alternative binding modes. BMC Struct Biol 2015;15:9. [PMID: 25957175 DOI: 10.1186/s12900-015-0036-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
87 Hayakawa K, Sakamoto Y, Kanie O, Ohtake A, Daikoku S, Ito Y, Shiota K. Reactivation of hyperglycemia-induced hypocretin (HCRT) gene silencing by N-acetyl-d-mannosamine in the orexin neurons derived from human iPS cells. Epigenetics 2017;12:764-78. [PMID: 28762874 DOI: 10.1080/15592294.2017.1346775] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
88 Luong L, Carrive P. Orexin microinjection in the medullary raphe increases heart rate and arterial pressure but does not reduce tail skin blood flow in the awake rat. Neuroscience 2012;202:209-17. [DOI: 10.1016/j.neuroscience.2011.11.073] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis]
89 Morrison SF, Madden CJ, Tupone D. An orexinergic projection from perifornical hypothalamus to raphe pallidus increases rat brown adipose tissue thermogenesis. Adipocyte 2012;1:116-20. [PMID: 23538704 DOI: 10.4161/adip.19736] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
90 Guyenet PG, Abbott SB. Chemoreception and asphyxia-induced arousal. Respir Physiol Neurobiol 2013;188:333-43. [PMID: 23608705 DOI: 10.1016/j.resp.2013.04.011] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
91 Wang Z, Liu S, Kakizaki M, Hirose Y, Ishikawa Y, Funato H, Yanagisawa M, Yu Y, Liu Q. Orexin/hypocretin activates mTOR complex 1 (mTORC1) via an Erk/Akt-independent and calcium-stimulated lysosome v-ATPase pathway. J Biol Chem 2014;289:31950-9. [PMID: 25278019 DOI: 10.1074/jbc.M114.600015] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
92 Gascuel J, Lemoine A, Rigault C, Datiche F, Benani A, Penicaud L, Lopez-Mascaraque L. Hypothalamus-olfactory system crosstalk: orexin a immunostaining in mice. Front Neuroanat 2012;6:44. [PMID: 23162437 DOI: 10.3389/fnana.2012.00044] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
93 Xu T, Yang Y, Ward R, Gao L, Liu Y. Orexin receptors: Multi-functional therapeutic targets for sleeping disorders, eating disorders, drug addiction, cancers and other physiological disorders. Cellular Signalling 2013;25:2413-23. [DOI: 10.1016/j.cellsig.2013.07.025] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 7.6] [Reference Citation Analysis]
94 Snyder E, Ma J, Svetnik V, Connor KM, Lines C, Michelson D, Herring WJ. Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase 3 data. Sleep Med 2016;19:93-100. [PMID: 27198953 DOI: 10.1016/j.sleep.2015.10.007] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
95 Anegawa E, Kotorii N, Ishimaru Y, Okuro M, Sakai N, Nishino S. Chronic Powder Diet After Weaning Induces Sleep, Behavioral, Neuroanatomical, and Neurophysiological Changes in Mice. PLoS One 2015;10:e0143909. [PMID: 26630494 DOI: 10.1371/journal.pone.0143909] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
96 Bland H, Li X, Mangin E, Yee KL, Lines C, Herring WJ, Gillespie G. Effects of Bedtime Dosing With Suvorexant and Zolpidem on Balance and Psychomotor Performance in Healthy Elderly Participants During the Night and in the Morning. J Clin Psychopharmacol 2021;41:414-20. [PMID: 34181362 DOI: 10.1097/JCP.0000000000001439] [Reference Citation Analysis]
97 Li A, Nattie E. Orexin, cardio-respiratory function, and hypertension. Front Neurosci 2014;8:22. [PMID: 24574958 DOI: 10.3389/fnins.2014.00022] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
98 Kim SJ, Pilowsky PM, Farnham MM. Intrathecal Intermittent Orexin-A Causes Sympathetic Long-Term Facilitation and Sensitizes the Peripheral Chemoreceptor Response to Hypoxia in Rats. J Pharmacol Exp Ther 2016;358:492-501. [PMID: 27384072 DOI: 10.1124/jpet.116.234443] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
99 Winrow CJ, Gotter AL, Cox CD, Doran SM, Tannenbaum PL, Breslin MJ, Garson SL, Fox SV, Harrell CM, Stevens J, Reiss DR, Cui D, Coleman PJ, Renger JJ. Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist. J Neurogenet 2011;25:52-61. [PMID: 21473737 DOI: 10.3109/01677063.2011.566953] [Cited by in Crossref: 179] [Cited by in F6Publishing: 166] [Article Influence: 16.3] [Reference Citation Analysis]
100 Slats D, Claassen JA, Verbeek MM, Overeem S. Reciprocal interactions between sleep, circadian rhythms and Alzheimer's disease: focus on the role of hypocretin and melatonin. Ageing Res Rev 2013;12:188-200. [PMID: 22575905 DOI: 10.1016/j.arr.2012.04.003] [Cited by in Crossref: 70] [Cited by in F6Publishing: 70] [Article Influence: 7.8] [Reference Citation Analysis]
101 Killeen PR, Russell VA, Sergeant JA. A behavioral neuroenergetics theory of ADHD. Neurosci Biobehav Rev 2013;37:625-57. [PMID: 23454637 DOI: 10.1016/j.neubiorev.2013.02.011] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 5.3] [Reference Citation Analysis]
102 Chung JYL, Zhong Y, Maloney KM, Reamer RA, Moore JC, Strotman H, Kalinin A, Feng R, Strotman NA, Xiang B, Yasuda N. Unusual Pyrimidine Participation: Efficient Stereoselective Synthesis of Potent Dual Orexin Receptor Antagonist MK-6096. Org Lett 2014;16:5890-3. [DOI: 10.1021/ol5028249] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
103 Girard F, Meszar Z, Marti C, Davis FP, Celio M. Gene expression analysis in the parvalbumin-immunoreactive PV1 nucleus of the mouse lateral hypothalamus: Parvalbumin in the lateral hypothalamus. European Journal of Neuroscience 2011;34:1934-43. [DOI: 10.1111/j.1460-9568.2011.07918.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
104 Arrigoni E, Chen MC, Fuller PM. The anatomical, cellular and synaptic basis of motor atonia during rapid eye movement sleep. J Physiol 2016;594:5391-414. [PMID: 27060683 DOI: 10.1113/JP271324] [Cited by in Crossref: 32] [Cited by in F6Publishing: 10] [Article Influence: 5.3] [Reference Citation Analysis]
105 Qiao SN, Zhou W, Liu LL, Zhang DQ, Zhong YM. Orexin-A Suppresses Signal Transmission to Dopaminergic Amacrine Cells From Outer and Inner Retinal Photoreceptors. Invest Ophthalmol Vis Sci 2017;58:4712-21. [PMID: 28910447 DOI: 10.1167/iovs.17-21835] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
106 de Boer A, Ter Horst GJ, Lorist MM. Physiological and psychosocial age-related changes associated with reduced food intake in older persons. Ageing Res Rev 2013;12:316-28. [PMID: 22974653 DOI: 10.1016/j.arr.2012.08.002] [Cited by in Crossref: 81] [Cited by in F6Publishing: 67] [Article Influence: 9.0] [Reference Citation Analysis]
107 Roundtree HM, Simeone TA, Johnson C, Matthews SA, Samson KK, Simeone KA. Orexin Receptor Antagonism Improves Sleep and Reduces Seizures in Kcna1-null Mice. Sleep 2016;39:357-68. [PMID: 26446112 DOI: 10.5665/sleep.5444] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
108 Hsieh KC, Gvilia I, Kumar S, Uschakov A, McGinty D, Alam MN, Szymusiak R. c-Fos expression in neurons projecting from the preoptic and lateral hypothalamic areas to the ventrolateral periaqueductal gray in relation to sleep states. Neuroscience 2011;188:55-67. [PMID: 21601616 DOI: 10.1016/j.neuroscience.2011.05.016] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
109 Guyenet PG. Regulation of breathing and autonomic outflows by chemoreceptors. Compr Physiol 2014;4:1511-62. [PMID: 25428853 DOI: 10.1002/cphy.c140004] [Cited by in Crossref: 153] [Cited by in F6Publishing: 139] [Article Influence: 21.9] [Reference Citation Analysis]
110 Kaushik MK, Aritake K, Cherasse Y, Imanishi A, Kanbayashi T, Urade Y, Yanagisawa M. Induction of narcolepsy-like symptoms by orexin receptor antagonists in mice. Sleep 2021:zsab043. [PMID: 33609365 DOI: 10.1093/sleep/zsab043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
111 Liu F, Xu G, Wang L, Jiang S, Yang X, Zhong Y. Gene expression and protein distribution of orexins and orexin receptors in rat retina. Neuroscience 2011;189:146-55. [DOI: 10.1016/j.neuroscience.2011.04.011] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
112 Rao Y, Mineur YS, Gan G, Wang AH, Liu ZW, Wu X, Suyama S, de Lecea L, Horvath TL, Picciotto MR, Gao XB. Repeated in vivo exposure of cocaine induces long-lasting synaptic plasticity in hypocretin/orexin-producing neurons in the lateral hypothalamus in mice. J Physiol 2013;591:1951-66. [PMID: 23318871 DOI: 10.1113/jphysiol.2012.246983] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
113 Torterolo P, Sampogna S, Chase MH. Hypocretinergic and non-hypocretinergic projections from the hypothalamus to the REM sleep executive area of the pons. Brain Res 2013;1491:68-77. [PMID: 23122879 DOI: 10.1016/j.brainres.2012.10.050] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
114 Cheng X, Wu J, Geng M, Xiong J. Role of synaptic activity in the regulation of amyloid beta levels in Alzheimer's disease. Neurobiol Aging 2014;35:1217-32. [PMID: 24368087 DOI: 10.1016/j.neurobiolaging.2013.11.021] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
115 Winrow CJ, Gotter AL, Cox CD, Tannenbaum PL, Garson SL, Doran SM, Breslin MJ, Schreier JD, Fox SV, Harrell CM, Stevens J, Reiss DR, Cui D, Coleman PJ, Renger JJ. Pharmacological characterization of MK-6096 – A dual orexin receptor antagonist for insomnia. Neuropharmacology 2012;62:978-87. [DOI: 10.1016/j.neuropharm.2011.10.003] [Cited by in Crossref: 91] [Cited by in F6Publishing: 91] [Article Influence: 9.1] [Reference Citation Analysis]
116 Liu F, Weng SJ, Yang XL, Zhong YM. Orexin-A potentiates L-type calcium/barium currents in rat retinal ganglion cells. Neuroscience 2015;305:225-37. [PMID: 26259903 DOI: 10.1016/j.neuroscience.2015.08.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]